Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
Active, not recruiting · Phase 2 · NCT06052176
Conditions: Cirrhosis, Hepatic Encephalopathy
At a glance
- Research payments reported, 2025
- $6,962
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 25
About the trial
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center (with Grifols Biologicals, LLC)
- Tested
- Albumin Infusion (drug)
- Dates
- Started 2023-11-02; completion 2026-12-01
- Results posted
- Not yet
Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial changes. This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over 8 weeks with biological sampling and cognitive and health related quality of life (HRQOL) testing with each subject acting as their own control.
From ClinicalTrials.gov, last updated 2026-08-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Grifols Shared Services North America, Inc. reported $6,962 in research payments for this study in 2025 (1 payments).
Products named: Albutein
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mcguire Research Institute Inc $6,962
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.